Exhale

The official blog of the Lung Institute.

What is the Cause of Bronchiectasis?

What is the Cause of Bronchiectasis

Bronchiectasis is a lung disease characterized by the scarring and widening of the lungs’ airways. The airways then lose their ability to clear out mucus, which in turn causes mucus to build up, creating a blockage that can become a breeding ground for bacteria growth. This lung condition is usually accompanied by reoccurring infections as a result of the bacteria, which cause continuous inflammation and weakened air passages over time.

There are several causes of bronchiectasis, one of the most common being the genetic cystic fibrosis condition. Other common causes of bronchiectasis include:

  • Traumatic injury to the lungs
  • Tumors or other foreign developments in the lungs
  • Autoimmune diseases like rheumatoid arthritis
  • Abnormalities that prevent the cilia in the lungs from removing excess mucus
  • Immunodeficiency disorders such as AIDS and HIV
  • Allergic bronchopulmonary aspergillosis
  • Connective tissue diseases like Crohn’s disease
  • Chronic obstructive pulmonary disease (COPD)
  • Alpha-1 antitrypsin deficiency

While there is currently no cure for bronchiectasis, there are many treatment options available to help patients manage symptoms and live with the effects of this lung disease. Traditional treatment options for this condition include oral medications aimed at thinning mucus and treating infection, inhaled medicines (including bronchodilators and corticosteroids) and oxygen therapy. At the Lung Institute, we offer an alternative form of bronchiectasis treatment with our innovative cellular therapy. This natural approach to treatment utilizes cells from the patient’s own body to potentially slow the progression of the disease and naturally improve lung function.

If you have been diagnosed with bronchiectasis and would like to explore cellular therapy as an alternative treatment option, contact the Lung Institute today at (800) 729-3065.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.